AnthonyMartinMillsMD

PubMed

• 34 citations
  Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, F...
  Debbie Hagins, Chloe Orkin, Eric S. Daar, Anthony Mills, Cynthia Brinson, Edwin DeJesus, Frank A. Post, Morales-Ramirez J, Melanie A. Thompson, Olayemi Osiyemi, B. Ras...> ;HIV Medicine. 2018 Aug 12
• 5 citations
  Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.
  Paul E. Sax, Edwin DeJesus, Gordon Crofoot, Douglas J. Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Xuelian Wei, Sean E Collins, Andrew T. A. Cheng> ;AIDS. 2018 Jul 31
• 63 citations
  A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
  Joseph J. Eron, Chloe Orkin, Joel E. Gallant, Jean-Michel Molina, Eugenia Negredo, Andrea Antinori, Anthony Mills, Jacques Reynes, Erika Van Landuyt, Erkki Lathouwers,...> ;AIDS. 2018 Jul 17
• 89 citations
  Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HI...
  Molina, J. M., Molina, J. M., Molina, J. M., Molina, J. M., Ward, D., Ward, D., Ward, D., Ward, D., Brar, I., Brar, I., Brar, I., Brar, I., Mills, A., Mills, A., Mills...> ;The lancet. HIV. 2018 Jun 22
• 68 citations
  Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of...
  Edwin DeJesus, Bernard Haas, Sorana Segal-Maurer, Moti Ramgopal, Anthony Mills, Nicolas A. Margot, Ya-Pei Liu, Tariro Makadzange, Scott McCallister> ;AIDS Research and Human Retroviruses. 2018 Apr 1
• 44 citations
  Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfecte...
  Joel E. Gallant, Jason Brunetta, Gordon Crofoot, Paul Benson, Anthony Mills, Cynthia Brinson, Shinichi Oka, Andrew K. Cheng, Will Garner, Marshall W. Fordyce, Moupali ...> ;Journal of Acquired Immune Deficiency Syndromes. 2016 Nov 1
• 126 citations
  Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 ...
  Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, A. Scribner, David Shamblaw, Michael S. Saag, Huyen Cao, Hal Martin, Moupali D...> ;Journal of Acquired Immune Deficiency Syndromes. 2015 Aug 1
• 11 citations
  Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobic...
  Anthony Mills, Will Garner, Anton Pozniak, Juan Berenguer, Rebecca M. Speck, Randall Bender, Thai Nguyen> ;The Patient. 2015 Jun 5
• 16 citations
  Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumara...
  Anthony Mills, G. Crofoot, Roberto Ortiz, Bruce Rashbaum, William J. Towner, Douglas J. Ward, Cynthia Brinson, Rohit N. Kulkarni, William Garner, Ramin Ebrahimi, Huyen...> ;HIV Clinical Trials. 2014 Dec 22
• 252 citations
  Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
  Antonella Castagna, Franco Maggiolo, Giovanni Penco, David Wright, Anthony Mills, Robert M. Grossberg, Jean-Michel Molina, Julie Chas, J. Durant, Santiago Moreno, Manu...> ;The Journal of Infectious Diseases. 2014 Aug 1
• 81 citations
  Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabi...
  Anton Pozniak, Martin Markowitz, Anthony Mills, Hans-Juergen Stellbrink, Antonio Antela, Pere Domingo, Pierre-Marie Girard, Keith Henry, Thai Nguyen, David Piontkowsky...> ;The Lancet. Infectious Diseases. 2014 Jul 1
• 84 citations
  A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/...
  David A. Wohl, Calvin J. Cohen, Joel E. Gallant, Anthony Mills, Paul E. Sax, Edwin DeJesus, Andrew R. Zolopa, Hui C. Liu, Andrew Plummer, Kirsten L. White, Andrew K. C...> ;Journal of Acquired Immune Deficiency Syndromes. 2014 Mar 1
• 64 citations
  Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
  Anthony Mills, Calvin J. Cohen, Edwin DeJesus, Cynthia Brinson, Scott Williams, Kitty Yale, Srini Ramanathan, Maggie H. Wang, Kirsten L. White, Susan K. Chuck, Andrew ...> ;HIV Clinical Trials. 2013 Sep 1
• 34 citations
  Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment‐naïve, HIV‐1‐infected patients at 48 weeks
  Anthony Mills, Andrea Antinori, Bonaventura Clotet, Jan Fourie, G Herrera, Charles B. Hicks, José Valdez Madruga, Simon Vanveggel, Marita Stevens, Katia Boven, Echo, T...> ;HIV Medicine. 2013 Aug 1
• 57 citations
  Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies
  Mark Nelson, Richard Elion, C Cohen, Anthony Mills, Sally Hodder, Sorana Segal-Maurer, Mark Bloch, Will Garner, B. Guyer, S. Williams, Susan K. Chuck, Simon Vanveggel,...> ;HIV Clinical Trials. 2013 May 1
• 127 citations
  A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disop...
  Andrew R. Zolopa, Paul E. Sax, Edwin DeJesus, Anthony Mills, Calvin J. Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Andrew Plummer, Kirsten L. White, Andrew K. C...> ;Journal of Acquired Immune Deficiency Syndromes. 2013 May 1
• 34 citations
  Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
  Anthony Mills, Donna Mildvan, Daniel Podzamczer, Gerd Fätkenheuer, Manuel Leal, Soe Than, Srinivas Rao Valluri, Charles Craig, Lynn McFadyen, Manoli Vourvahis, Jayvant...> ;Journal of Acquired Immune Deficiency Syndromes. 2013 Feb 1
• 348 citations
  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infect...
  Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew R. Zolopa, Calvin J. Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten L. White, Br...> ;Lancet. 2012 Jun 30
• 213 citations
  Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
  Anthony M. Mills, Mark T. Nelson, Dushyantha Jayaweera, Kiat Ruxrungtham, Isabel Cassetti, Pierre Marie Girard, Cassy Workman, Inge Dierynck, Vanitha Sekar, Carline Va...> ;AIDS. 2009 Aug 24
• 57 citations
  Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
  Jeffrey P. Nadler, Daniel S Berger, Gary Blick, Cimoch Pj, Cohen Cj, Greenberg Rn, Charles B. Hicks, Richard M. W. Hoetelmans, Iveson Kj, Jayaweera Ds, Anthony Mills, ...> ;AIDS. 2007 Mar 30
• Join now to see all